Daniel Gold, MD
Otolaryngology · White Plains, NYNPI 1902927312
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,189 of the $3,646 with a category attached, or 87.5%. It is spread thinly across 23 manufacturers, the largest accounting for just 22.4% — the pattern of someone who eats at a lot of different presentations.
Across 138 payments — averaging $26.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Optinose US, Inc.$817
- GSK$796
- Aerin Medical Inc.$491
- Novartis$434
- Stryker$247
- Sanofi$129
- plus $730 from 17 others
Across 10 payments — averaging $7774.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$48K
- Otonomy, Inc.$30K
What the payments were for
- Speaking & faculty fees$40011%
- Food & beverage$3,18987%
- Education$572%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Optinose US, Inc. | 40 | $817 |
| GSK | 29 | $796 |
| Aerin Medical Inc. | 3 | $491 |
| Novartis | 23 | $434 |
| Stryker | 6 | $247 |
| Sanofi | 5 | $129 |
| Abbott | 2 | $112 |
| Hikma Pharmaceuticals USA | 4 | $91 |
| Inspire Medical Systems, Inc. | 3 | $87 |
| Amgen | 3 | $66 |
| AstraZeneca | 5 | $65 |
| Sanofi-aventis U.S. LLC | 1 | $57 |
| Regeneron Healthcare Solutions, Inc. | 3 | $47 |
| Smith+Nephew | 2 | $42 |
| Integra Lifesciences Corporation | 1 | $26 |
| Neurent Medical Limited | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $19 |
| Acclarent, Inc | 1 | $18 |
| Grifols USA, LLC | 1 | $16 |
| Dentsply Sirona Inc | 1 | $15 |
| Acelrx Pharmaceuticals, Inc. | 1 | $14 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vivaer RF Stylus$400
How this compares
$3,646 in reported general payments places this provider in the 75th percentile of 701 otolaryngology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 15 | $83,863 |
| XhanceFluticasone Propionate | 18 | $16,547 |
| Ipratropium Bromide | 327 | $8,885 |
| Azelastine Hcl | 250 | $8,022 |
| Fluticasone Propionate | 188 | $2,560 |
| Ofloxacin | 36 | $1,774 |
| Famotidine | 165 | $1,748 |
| Prednisolone Acetate | 33 | $1,336 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 12 | $1,202 |
| Levocetirizine Dihydrochloride | 33 | $1,024 |
| Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort | 19 | $892 |
| Triamcinolone Acetonide | 39 | $859 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 36 | $777 |
| Montelukast Sodium | 84 | $744 |
| Cefdinir | 33 | $742 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Optinose US, Inc.Xhance | $817 | $16,54718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 701 otolaryngology providers in New York.
Other otolaryngology in White Plains
- Nitin BhatiaWhite Plains$120K
- Robert KellmanSyracuse$2.5M
- Roheen RaithathaNew York$830K
- Nora PerkinsAlbany$300K
- Moshe EphratNew Hyde Park$250K
- Gavin SetzenAlbany$243K
- Habibullah JamalRye Brook$179K
- Albert JenFlushing$171K
- Dennis KrausNew York$159K
- Sveta KarelskyRochester$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.